Top Stories
Felzartamab was approved in combination with lenalidomide and dexamethasone to treat adults with multiple myeloma who have received at least one prior line of therapy.
The combined company, Fibrx Therapeutics, will start a Phase II trial of RXC008 in fibrostenotic Crohn’s disease.
After a bruising FDA adcom, CEO says the US regulator is willing to review an amended filing focused on upper-limb function.
Rusfertide is being developed by Zealand and Protagonist to treat polycythemia vera.
Zenbexus (iberdomide) is also the first drug granted accelerated approval based on minimal residual disease-negative complete response.
Conference News
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical a...
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval --ATLA...
STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics f...
- Completed quarter with $26.9 million in cash and restricted cash- Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic i...
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p...
